{"id":"NCT00981682","sponsor":"Serenity Pharmaceuticals, Inc.","briefTitle":"Long Term Safety Assessment of SER120 in Patients With Nocturia","officialTitle":"A Phase III Open-Label Extension Study to Investigate the Safety of SER120 Nasal Spray Formulations in Patients With Nocturia Completing Study SPC-SER120-DB1-200901 or Study SPC-SER120-DB2-200902","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2009-08","primaryCompletion":"2011-06","completion":"2011-08","firstPosted":"2009-09-22","resultsPosted":"2021-01-20","lastUpdate":"2021-01-20"},"enrollment":376,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Nocturia"],"interventions":[{"type":"DRUG","name":"SER120","otherNames":[]}],"arms":[{"label":"SER120 (desmopressin)","type":"EXPERIMENTAL"}],"summary":"The hypothesis of this study is that SER120 is safe and well tolerated for use in nocturic patients.","primaryOutcome":{"measure":"Mean Serum Sodium","timeFrame":"40 weeks","effectByArm":[{"arm":"SER120 750 mcg","deltaMin":0,"sd":2.3}],"pValues":[]},"eligibility":{"minAge":"50 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":2,"exclusionCount":5},"locations":{"siteCount":1,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":30,"n":376},"commonTop":["Nasal discomfort","sneezing","Rhinorrhea","headache","Upper respiratory infection"]}}